Armed antibodies for cancer treatment: A promising tool in a changing era

Cancer Immunology, Immunotherapy

Volumn 64, Issue 1, 2015, Pages 113-121

  Danielli, Riccardo ^a   Patuzzo, Roberto ^b   Ruffini, Pier Adelchi ^c   Maurichi, Andrea ^b   Giovannoni, Leonardo ^d   Elia, Giuliano ^d   Neri, Dario ^e   Santinami, Mario ^b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Chemistry Section   (Italy)

^d Philogen SpA   (Italy)

^e ETH ZURICH   (Switzerland)

Author keywords

Armed antibodies; Immunocytokines; Intralesional immunotherapy; NIBIT 2013

Indexed keywords

CYTARABINE; DACARBAZINE; DARLEUKIN; DOXORUBICIN; FIBROMUN; GEMCITABINE; IMMUNOCYTOKINE; IPILIMUMAB; MELPHALAN; PACLITAXEL; TELEUKIN; CYTOKINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MELANOMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOLID TUMOR; THERAPEUTIC INDEX; TUMOR IMMUNOLOGY; ANIMAL; DRUG DELIVERY SYSTEM; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; MELANOMA; RECOMBINANT FUSION PROTEINS;

EID: 84925028550     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1621-0     Document Type: Review

References (58)

1. Krall N, Scheuermann J, Neri D (2013) Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed Engl 52(5): 1384-1402. doi: 10. 1002/anie. 201204631.
2. van der Veldt AA, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, van der Hoeven JJ, Windhorst AD, Lammertsma AA, Lubberink M (2010) Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 37(10): 1950-1958. doi: 10. 1007/s00259-010-1489-y.
3. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, Williams S, Cole MJ, Ross S, Schwall R (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 67(1): 254-261. doi: 10. 1158/0008-5472. CAN-06-2531.
4. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA (2008) Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14(17): 5610-5618. doi: 10. 1158/1078-0432. CCR-08-0116.
5. Pasche N, Neri D (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17(11-12): 583-590. doi: 10. 1016/j. drudis. 2012. 01. 007.
6. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2): 147-159. doi: 10. 1038/nrd1957.
7. Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 5(201): 201ra118. doi: 10. 1126/scitranslmed. 3006221.
8. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5(6): 436-446. doi: 10. 1038/nrc1627.
9. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Durkop H, Menssen HD (2009) Expression of the oncofetal ED-Bcontaining fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113(10): 2265-2274. doi: 10. 1182/blood-2008-06-160416.
10. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102(1): 75-85. doi: 10. 1002/ijc. 10662.
11. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99(5): 1659-1665. doi: 10. 1182/blood. V99. 5. 1659.
12. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20(3): 264-269. doi: 10. 1038/nbt0302-264.
13. Hemmerle T, Neri D (2014) The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer 134(2): 467-477. doi: 10. 1002/ijc. 28359.
14. Hemmerle T, Probst P, Giovannoni L, Green AJ, Meyer T, Neri D (2013) The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer 109(5): 1206-1213. doi: 10. 1038/bjc. 2013. 421.
15. Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14(20): 6515-6524. doi: 10. 1158/1078-0432. CCR-07-5041.
16. Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D (2012) The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 18(15): 4092-4103. doi: 10. 1158/1078-0432. CCR-12-0282.
17. Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D (2009) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113(10): 2275-2283. doi: 10. 1182/blood-2008-05-160747.
18. Hess C, Venetz D, Neri D (2014) Emerging classes of armed antibody therapeutics against cancer. Med Chem Commun 5(4): 408-431. doi: 10. 1039/C3MD00360D.
19. Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14(2): 157-163.
20. Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4): 616-632.
21. Vrouenraets BC, Nieweg OE, Kroon BB (1996) Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83(10): 1319-1328.
22. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM III, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL Jr, Chadaram V, Herndon JE II, Fraker DL, Tyler DS, American College of Surgeons Oncology Group Trial Z (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24(25): 4196-4201. doi: 10. 1200/JCO. 2005. 05. 5152.
23. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224(6): 756-764; discussion 764-765.
24. Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14(10): 2653-2665.
25. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO (1993) Regional therapy of melanoma. Eur J Cancer 29A(4): 606-612.
26. Bonvalot S, Laplanche A, Lejeune F, Stoeckle E, Le Pechoux C, Vanel D, Terrier P, Lumbroso J, Ricard M, Antoni G, Cavalcanti A, Robert C, Lassau N, Blay JY, Le Cesne A (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16(7): 1061-1068. doi: 10. 1093/annonc/mdi229.
27. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AM (1999) Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80(1-2): 161-166. doi: 10. 1038/sj. bjc. 6690335.
28. Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM (1993) Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80(8): 995-997.
29. Rossi CR, Foletto M, Mocellin S, Pilati P, Lise M (2004) Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 11(2): 173-177.
30. Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, Ventura E, Gonzalez-Iglesias R, Lovato V, Giovannoni L, Tasciotti A, Neri D, Santinami M, Menssen HD, De Cian F (2013) Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol 107(2): 173-179. doi: 10. 1002/jso. 23168.
31. Testori A, Faries MB, Thompson JF, Pennacchioli E, Deroose JP, van Geel AN, Verhoef C, Verrecchia F, Soteldo J (2011) Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 104(4): 391-396. doi: 10. 1002/jso. 22029.
32. Hersey P, Gallagher S (2014) Intralesional immunotherapy for melanoma. J Surg Oncol 109(4): 320-326. doi: 10. 1002/jso. 23494.
33. Si Z, Hersey P, Coates AS (1996) Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6(3): 247-255.
34. von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61(6): 1071-1074.
35. Kubo H, Ashida A, Matsumoto K, Kageshita T, Yamamoto A, Saida T (2008) Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res 300(6): 297-301. doi: 10. 1007/s00403-008-0841-6.
36. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89(9): 1620-1626. doi: 10. 1038/sj. bjc. 6601320.
37. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pfohler C, Pawelec G, Garbe C (2010) High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116(17): 4139-4146. doi: 10. 1002/cncr. 25156.
38. Boyd KU, Wehrli BM, Temple CL (2011) Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 104(7): 711-717. doi: 10. 1002/jso. 21968.
39. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, Carretero G (2009) Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2. Actas Dermosifiliogr 100(7): 571-585.
40. Gutwald JG, Groth W, Mahrle G (1994) Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma. Br J Dermatol 130(4): 541-542.
41. Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C (2014) Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res 2(7): 668-678. doi: 10. 1158/2326-6066. CIR-13-0206.
42. Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 133(3): 751-758. doi: 10. 1038/jid. 2012. 376.
43. Pretto F, Elia G, Castioni N, Neri D (2014) Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother 63(9): 901-910. doi: 10. 1007/s00262-014-1562-7.
44. Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology 23(6): 488-496.
45. van Horssen R, Ten Hagen TL, Eggermont AM (2006) TNFalpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11(4): 397-408. doi: 10. 1634/theoncologist. 11-4-397.
46. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45(2): 228-247. doi: 10. 1016/j. ejca. 2008. 10. 026.
47. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23): 7412-7420. doi: 10. 1158/1078-0432. CCR-09-1624.
48. Di Giacomo AM, Calabro L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, Biagioli M, Altomonte M, Maio M (2013) Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 62(6): 1021-1028. doi: 10. 1007/s00262-013-1418-6.
49. Kaufman HL (2014) Melanoma as a model for precision medicine in oncology. Lancet Oncol 15(3): 251-253. doi: 10. 1016/S1470-2045(14)70059-2.
50. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, investigators MDX (2013) Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 19(8): 2232-2239. doi: 10. 1158/1078-0432. CCR-12-3080.
51. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723. doi: 10. 1056/NEJMoa1003466.
52. Robert C, Thomas L, Bondarenko I, O'Day S, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (26): 2517-2526. doi: 10. 1056/NEJMoa1104621.
53. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group B-S (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507-2516. doi: 10. 1056/NEJMoa1103782.
54. Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D (2014) Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol 15(3): 297-304. doi: 10. 1016/S1470-2045(14)70007-5.
55. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839): 358-365. doi: 10. 1016/S0140-6736(12)60868-X.
56. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, Gonzalez-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F (2010) The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 46(16): 2926-2935. doi: 10. 1016/j. ejca. 2010. 07. 033.
57. Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, Gonzalez-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C (2011) A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 17(24): 7732-7742. doi: 10. 1158/1078-0432. CCR-11-1203.
58. Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, Gonzalez-Iglesias R, Giovannoni L, Tasciotti A, Neri D, Menssen HD, de Braud F (2013) Phase I/II study of the tumourtargeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clinical Oncol 139(3): 447-455. doi: 10. 1007/s00432-012-1327-7.